Have a personal or library account? Click to login
Evaluation of COVID-19 protease and HIV inhibitors interactions Cover

Evaluation of COVID-19 protease and HIV inhibitors interactions

Acta Pharmaceutica
Volume 72 (2022): Issue 1 (March 2022)
By: Linh Tran,  Dao Ngoc Hien Tam,  Heba Elhadad,  Nguyen Minh Hien and  Nguyen Tien Huy  
Open Access
|Aug 2021

Authors

Linh Tran

trantthuylinh10@duytan.edu.vn

Institute of Fundamental and Applied Sciences, Duy Tan University
Faculty of Natural Sciences, Duy Tan University

Dao Ngoc Hien Tam

Asia Shine Trading & Service Co. Ltd

Heba Elhadad

Department of Parasitology, Medical Research Institute, Alexandria University, Alexandria, Egypt

Nguyen Minh Hien

School of Medicine, Vietnam National University

Nguyen Tien Huy

Department of Clinical Product Development, Institute of Tropical Medicine, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
DOI: https://doi.org/10.2478/acph-2022-0010 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 1 - 8
Accepted on: Feb 27, 2021
Published on: Aug 30, 2021
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
COVID-19,
SARS-CoV-2,
docking study,
anti-HIV drugs,
protease inhibitors
Related subjects:
Pharmacy,
Pharmacy, other

© 2021 Linh Tran, Dao Ngoc Hien Tam, Heba Elhadad, Nguyen Minh Hien, Nguyen Tien Huy, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 72 (2022): Issue 1 (March 2022)Next article